Maximo Rocha - Omnicell Senior Officer
| OMCL Stock | USD 40.15 0.59 1.49% |
Executive
Maximo Rocha is Senior Officer of Omnicell
| Address | 4220 North Freeway, Fort Worth, TX, United States, 76137 |
| Phone | 877 415 9990 |
| Web | https://www.omnicell.com |
Omnicell Management Efficiency
The value of Return On Tangible Assets is estimated to slide to 0. The value of Return On Capital Employed is expected to slide to 0. At this time, Omnicell's Net Tangible Assets are quite stable compared to the past year. Deferred Long Term Asset Charges is expected to rise to about 8.9 M this year, although the value of Intangible Assets will most likely fall to about 126.2 M. Omnicell's management efficiency ratios could be used to measure how well Omnicell manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| John Vong | Astrana Health | 51 | |
| Glenn Sobotka | Astrana Health | 48 | |
| Nikolaos Nanis | Teladoc | 49 | |
| Steven Cook | Omada Health Common | 40 | |
| James Hart | Progyny | N/A | |
| Randy Wu | 10X Genomics | N/A | |
| Naveen Amar | SS Innovations International | ||
| Christopher Esq | UFP Technologies | 63 | |
| Gracye Cheng | Goodrx Holdings | N/A | |
| Minakshi Late | SS Innovations International | N/A | |
| Jens Durruthy | 10X Genomics | N/A | |
| Tom Scales | Omada Health Common | N/A | |
| Rahul Kumar | SS Innovations International | N/A | |
| Romin Nabiey | Goodrx Holdings | 39 | |
| Hilary Hatch | Phreesia | N/A | |
| Mennah Moustafa | 10X Genomics | N/A | |
| Scott Pope | Goodrx Holdings | N/A | |
| Aaron Crittenden | Goodrx Holdings | N/A | |
| Stella Sanchez | Teladoc | N/A | |
| Jaren Madden | Schrodinger | N/A | |
| Dave Ross | Teladoc | N/A | |
Management Performance
| Return On Equity | 0.0017 | ||||
| Return On Asset | 0.003 |
Omnicell Leadership Team
Elected by the shareholders, the Omnicell's board of directors comprises two types of representatives: Omnicell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Omnicell. The board's role is to monitor Omnicell's management team and ensure that shareholders' interests are well served. Omnicell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Omnicell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Spears, Principal Chief Accounting Officer | ||
| Kathleen Nemeth, Senior Relations | ||
| Tomer Stavitsky, Senior Officer | ||
| Stella Prefach, Senior Officer | ||
| Vicki MacDevitt, Chief Staff | ||
| Sara Dalmasso, Senior International | ||
| Jorge Taborga, Executive Vice President - Engineering | ||
| Perry Genova, Senior CTO | ||
| Minoo Mortazavi, Senior Operations | ||
| Corey Manley, Executive Officer | ||
| David Vanella, Senior Regulatory | ||
| Roxanne Turner, Sr Officer | ||
| Nchacha Etta, Executive CFO | ||
| Dave Ford, SVP Officer | ||
| Randall Lipps, Executive Chairman, CEO and Pres | ||
| Scott Seidelmann, Executive Vice President and Chief Commercial Officer | ||
| Nnamdi Njoku, Executive COO | ||
| Christine Mellon, Chief VP | ||
| Peter Kuipers, CFO, Executive Vice President | ||
| Baird III, Executive CFO | ||
| Brian Nutt, Chief VP | ||
| Maximo Rocha, Senior Officer | ||
| Giri Chodavarapu, Senior Officer |
Omnicell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Omnicell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0017 | ||||
| Return On Asset | 0.003 | ||||
| Profit Margin | 0 % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 1.35 B | ||||
| Shares Outstanding | 44.88 M | ||||
| Shares Owned By Insiders | 1.81 % | ||||
| Shares Owned By Institutions | 98.19 % | ||||
| Number Of Shares Shorted | 2.26 M | ||||
| Price To Earning | 64.95 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Omnicell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. For more information on how to buy Omnicell Stock please use our How to buy in Omnicell Stock guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omnicell. Anticipated expansion of Omnicell directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Omnicell assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.36) | Earnings Share 0.04 | Revenue Per Share | Quarterly Revenue Growth 0.023 | Return On Assets |
Understanding Omnicell requires distinguishing between market price and book value, where the latter reflects Omnicell's accounting equity. The concept of intrinsic value - what Omnicell's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Omnicell's price substantially above or below its fundamental value.
It's important to distinguish between Omnicell's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Omnicell should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Omnicell's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.